We enable longer and healthier living through detection and monitoring of serious disease
At Chembio, our mission is to be a leader in the development, manufacture and commercialization of diagnostic solutions. We are dedicated to delivering exceptional products that provide ease of use, and rapid and accurate results at the point-of-care (POC). As a global company, we are committed to innovation and the highest quality standards.
At the core of our commitment is our patented Next Generation DPP® (Dual Path Platform) technology. Our DPP® technology is a breakthrough in POC diagnostics, offering significant advantages over lateral-flow technologies including:
Significantly improved sensitivity
Multiplexing – multiple test results via a single blood sample (e.g., HIV-Syphilis Assay)
Application in a number of indications
Today our DPP® technology is the basis of multiple collaborations with healthcare innovators and leaders worldwide spanning infectious diseases such as HIV, Zika, Ebola, syphilis, malaria and febrile illness, as well as potential new uses in the diagnosis of a specific form of cancer and brain injury (concussion).
Closing share price